TABUK ENTERS INTO TRIPARTITE AGREEMENT WITH BOEHRINGER INGELHEIM AND CIGALAH
Tabuk has entered into a tripartite agreement with Boehringer Ingelheim, one of the world’s leading pharmaceutical companies, and Cigalah for local production in the Kingdom of Saudi Arabia. With this contract, Cigalah and Tabuk will manage and drive complex secondary packaging projects of 26 products for Boehringer Ingelheim.
The contract between the companies was signed by Dr. Abdul Aziz AL Serafi CEO consultant of Cigalah Group, Dr Hamad Al Khamees, General Manager Saudi Arabia Tabuk and Mohammed Al Tawil, General Manager, Boehringer Ingelheim Middle East and Near East Area.
Commenting on the agreement, Dr Hamad Al Khamees, General Manager Saudi Arabia Tabuk said “Being associated with a global brand like Boehringer Ingelheim and locally with Cigalah Group gives us an opportunity to best leverage our expertise in the local production space. We are excited about the opportunity given to us and look forward to more cooperation in the future with Boehringer Ingelheim.”
Mohammed Al Tawil, General Manager, Boehringer Ingelheim Middle East and Near East Area, commented, “We are delighted to enter into an agreement with Cigalah Group and Tabuk. As a leading global pharmaceutical company, we are committed to lead development and optimization of product specifications, testing protocols, qualification and validation of packaging thus ensuring product quality and safety. With this agreement we aim to reinforce our goal to make quality products and access to medication in the Kingdom.”
Dr. Abdul Aziz AL Serafi CEO consultant of Cigalah Group, said, “We are happy to be associated with Boehringer Ingelheim and are sure that the cooperation between the two companies will be beneficial for the pharmaceutical sector with regards to quality, safety and accessibility of medication in the Kingdom.”
The tripartite agreement enables Boehringer Ingelheim to contract Cigalah for the secondary packaging and authorizes Cigalah to implement and conduct the packaging production at Tabuk facilities.
Packaging is a highly regulated end stage of the drug production process aimed at not only safeguarding the drug against contamination but also ensuring its durability, visibility, sterility and strength. The partnership is aimed at optimization of the packaging process and providing medicines as finished goods which can help in reducing costs while maintaining the international product quality.